TeamDrive
RUS

Our projects

Team Drive is engaged in managing two large active projects under cooperation between the  Russian investment corporation RUSNANO which is currently implementing the national policy on the development of high-tech sectors and Domain Associates LLC., a leading US-based venture capital firm with an exclusive focus on life sciences. In March 2012 the partners announced the signing of an agreement to be subject to investments in innovative medical technologies.

To perform this task a subsidiary RMI Partners, a company specializing in managing pharmaceutical and medical projects, has been established by Team Drive.

RusnanoMedInvest

www.rmi.com.ru

RusnanoMedInvest (a subsidiary of RUSNANO) – was founded in March 2012 and is Russia’s and Eastern Europe’s largest venture capital company specializing in innovative developments in the field of pharmaceuticals and biotechnology. Initial funding - $ 380 mln.

Read more...


NovaMedica

www.novamedica.com

NovaMedica is a modern Russian pharmaceutical company established in 2012 by leading U.S. venture capital firm Domain Associates LLC and RUSNANO, an investment fund that implements state policy for the development of Russia’s high-technology industries. NovaMedica's strategy is focused on the search, registration and localization in Russia of innovative pharmaceutical products and technologies, as well as the development of the company’s own research and development activities and the establishment of a GMP-compliant pharmaceutical production facility in Russia.

Read more...


RMI Partners

www.rmivc.com

RMI Patners - a pharmaceutical project management company with a focus on investments to out of the box developments in medical, pharmaceutical and biotechnology sectors worldwide. The company’s key mission – to develop and introduce innovative drugs and medical equipment into the market and to create world-class Russian domiciled expertise in Life Sciences venture financing.

Read more...


The Network of Clinics "Doctor Ryadom"

www.drclinics.ru

Doctor Ryadom is a dynamically developed network of private clinics which was created in Moscow in 2014 by Team Drive and a group of private investors within public-private partnership with Moscow City Government.  The first clinic started its work in April 2014 in a new, densely populous district in South-East of Moscow. In less than a year Doctor Ryadom opened in such areas of Moscow 10 modern, well-equipped, multidimensional clinics for adults and children. 

Read more...

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more